Global Search | Novartis United States of America

Hide Filters

Showing 463 results

Media Release / Sep 11, 2020

Novartis presents data at ACTRIMS-ECTRIMS on the effects of treatment with Mayzent® (siponimod) studied on disability progression and cognitive processing speed in patients with progressing relapsing multiple sclerosis

Subgroup post hoc analysis of EXPAND reported that Mayzent reduced the risk of cognitive worsening and improved the chance of cognitive improvement at 6 months versus placebo in patients with…
Media Release / Mar 28, 2020

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified…
Media Release / Mar 28, 2020

Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

- Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months(1)- Prespecified…
Media Release / May 27, 2020

Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)

A post hoc analysis of Phase III ASCLEPIOS I and II trials showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0–12 months…
Media Release / May 07, 2011

Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET

- Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumors (NET) of pancreatic origin(1)- Afinitor represents a new approach to…
Media Release / Apr 11, 2011

Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows

Gilenya delayed the progression of disability both for patients who were previously treated for their MS and for patients who had not received prior treatment11 scientific abstracts on Gilenya…
Media Release / Apr 06, 2022

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized…
Media Release / Mar 24, 2022

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year…
Media Release / Mar 28, 2020

Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

- Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months(1)- Prespecified…
Media Release / Feb 11, 2020

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

- FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)(1)-…

Related News & Media